1.  2009 iMedia neuroScoop.net / anocef.org Chimiothérapie Khê Hoang-Xuan Paris

2.  2009 iMedia neuroScoop.net / anocef.org Bevacizumab (Avastin R ) Phase II study of Bevacizumab plus etoposide among recurrent malignant glioma patients Reardon DA et al (Duke, Durham) O128 = Beva + CPT11 Phase II study: Bevacizumab plus erlotinib in recurrent high grade glioma S. Sathornsumetee et al (Duke, Durham) O130 < Beva + CPT11 Phase II study Bevacizumab plus nitrosourea (fotemustine) in recurrent malignant gliomas Ruda R et al (Turin, Italie) O129 < ou = Beva + CPT11

3.  2009 iMedia neuroScoop.net / anocef.org Temozolomide (Témodal R ) Récidives A continuous schedule of TMZ for GBM at first relapse may overcome the therapeutic disadvantage of non methylated MGMT: results from the phase II Rescue trial Perry J et al (Canada) O128 Dose dense one week on/one week off temozolomide in recurrent glioma Taal W et al (Rotterdam) Traitement initial Phase II trial of Talamptel with standard radiation and TMZ in patients with newly diagnosed GBM : report of two year survival data Grossman SA et al (NABTT CNS consortium, Baltimore)

4.  2009 iMedia neuroScoop.net / anocef.org Cediranib (Recentin R ) A Phase I open label multicenter study to assess cediranib (Recentin TM) in combination with lomustine for patients with recurrent glioblastoma Batchelor T. et al (Boston) O126 Phase III en cours Cediranib versus lomustine versus Cediranib +lomustine A Phase IB trial of Cediranib in addition to standard TMZ plus radiation therapy in patients with newly diagnosed GBM. Chi AS (Boston)

5.  2009 iMedia neuroScoop.net / anocef.org EFFECTS OF PREGNANCY ON NATURAL HISTORY OF WHO GRADE II GLIOMAS: A quantitative analysis of the tumor growth rates L. Taillandier and The french ANOCEF group retrospective study N=14 / 26 Mean tumoral diameter over time Before Pregnancy: 3.4mm/year During Pregnancy: 5.8 mm/year P=0.0004Kinetic increase in 10 cases (8 G II, 2 G III) increase in 10 cases (8 G II, 2 G III)  75% stable in 4 cases (4 WHO grade II ) stable in 4 cases (4 WHO grade II )  25%  25% Négative impact on tumor growth in75% of cases